Literature DB >> 9593963

Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat.

D Wu1, J G Clement, W M Pardridge.   

Abstract

The blood-brain barrier (BBB) permeability to [3H]-azidodeoxythymidine (AZT), deoxythiacytidine (3TC), and thymidine was studied using both an intravenous injection/external organ (IV/EO) method and an internal carotid artery perfusion (ICAP) technique in parallel with [14C]-sucrose as a plasma volume marker. The brain volumes of distribution (VD) of the three compounds approximated that of sucrose with either method. Although the lipid solubility of AZT, as determined by the 1-octanol/buffer partition coefficient (P), was 16-fold higher than that of thymidine, the BBB permeability-surface area (PS) products were almost identical, consistent with preferential efflux of AZT from brain to blood. Copyright 1998Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593963     DOI: 10.1016/s0006-8993(98)00139-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

Review 2.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

3.  Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

Authors:  Susanne May; Scott Letendre; Richard Haubrich; J Allen McCutchan; Robert Heaton; Edmund Capparelli; Ronald Ellis
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-10       Impact factor: 4.147

4.  Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: tight junction proteins and transport properties.

Authors:  Lewis Zhichang Shi; G Jane Li; Shunzhen Wang; Wei Zheng
Journal:  Toxicol In Vitro       Date:  2007-07-28       Impact factor: 3.500

5.  Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.

Authors:  E V Batrakova; S Li; D W Miller; A V Kabanov
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

6.  Physicochemical selectivity of the BBB microenvironment governing passive diffusion--matching with a porcine brain lipid extract artificial membrane permeability model.

Authors:  Oksana Tsinman; Konstantin Tsinman; Na Sun; Alex Avdeef
Journal:  Pharm Res       Date:  2010-10-14       Impact factor: 4.200

7.  Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.

Authors:  M S Palombo; Y Singh; P J Sinko
Journal:  J Drug Deliv Sci Technol       Date:  2009       Impact factor: 3.981

8.  P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model.

Authors:  Claude Dagenais; Alex Avdeef; Oksana Tsinman; Adam Dudley; Richard Beliveau
Journal:  Eur J Pharm Sci       Date:  2009-07-08       Impact factor: 4.384

9.  Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.

Authors:  In Heon Lee; Matthew S Palombo; Xiaoping Zhang; Zoltan Szekely; Patrick J Sinko
Journal:  Eur J Pharm Biopharm       Date:  2018-06-09       Impact factor: 5.571

10.  Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain.

Authors:  Trevor Gerson; Edward Makarov; Thulani H Senanayake; Santhi Gorantla; Larisa Y Poluektova; Serguei V Vinogradov
Journal:  Nanomedicine       Date:  2013-07-09       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.